Effect of Opioid Abuse and Dependance on Outcomes of Patients Hospitalized With Copd: A 5-Year Analysis

Lara, Fernando Vazquez de; Rincon, F.; Pondaiah, Sathish; Freites, Christian Olivo; Pan, Di; Mathew, Joseph

doi:10.1016/j.chest.2018.08.695

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2018) reported no significant difference in length of pneumonia-related hospital stay between IDU and non-IDU patients (−.042 days, P = .825). 62 However, an increased likelihood of ventilation was found among IDU patients (OR: 1.45, P < .05). 62 Conversely, in a case-control study of 47,281 individuals, Tsai et al .…”

Section: Resultsmentioning

confidence: 88%

“… 62 However, an increased likelihood of ventilation was found among IDU patients (OR: 1.45, P < .05). 62 Conversely, in a case-control study of 47,281 individuals, Tsai et al . (2019) reported a significant increase in both cost and length of hospital stay among patients with pneumonia who injected drugs ($30,471 versus $16,020, P < .001; 5.7 days versus 3.7 days; P < .001).…”

Section: Resultsmentioning

confidence: 88%

See 1 more Smart Citation

Burden of vaccine-preventable diseases among at-risk adult populations in the US

Kolobova

Nyaku

Karakusevic

et al. 2022

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Life-course immunization holds significant benefit for population health by reducing the burden of vaccine-preventable diseases (VPD) through vaccinating individuals at different stages and circumstances in life. The study aimed to determine the epidemiologic, clinical, economic, and societal burden of VPDs among at-risk adult subpopulations in the United States. A systematic literature review was conducted for articles published between January 2010 and June 2020, which identified 72 publications. There was heterogeneity in available epidemiology data, with the prevalence of VPDs ranging from 1.1% to 68.7%. Where the disease burden was described, outcomes were typically worse among high-risk subpopulations than in the general population. Several VPDs, including herpes zoster, meningococcal, and pneumococcal infections were associated with increased costs. This review suggests that subpopulations may not frequently interact with the healthcare system, or their risk factors may not be recognized by healthcare providers, and therefore individuals may not be appropriately targeted for vaccination.

show abstract

Section: Resultsmentioning

confidence: 88%

Section: Resultsmentioning

confidence: 88%

Burden of vaccine-preventable diseases among at-risk adult populations in the US

Kolobova

Nyaku

Karakusevic

et al. 2022

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Nevertheless, retrospective population-based studies face inherent limitations, such as the inability to ascertain the specific reason for opioid use and to match controls for the severity of the treated individuals’ disease. Given that refractory dyspnea commonly prompts opioid use, and that dyspnea is closely correlated with mortality in COPD, the absence of adjustment for dyspnea severity in the analyses conducted by Ekstrom et al [ 62 ] and Vozoris et al [ 63 ] poses a significant risk of confounding by indication [ 64 , 65 , 66 ]. In both studies, it remains possible that opioid use merely indicated the presence of refractory dyspnea and signaled the severity of the underlying disease.…”

Section: Evidence Against the Use Of Opioids In Copdmentioning

confidence: 99%

Opioids in Treatment of Refractory Dyspnea in Chronic Obstructive Pulmonary Disease: Yes, No or Maybe

Rajnoveanu,

Harangus,

Todea

et al. 2024

JPM

View full text Add to dashboard Cite

Chronic Obstructive Pulmonary Disease (COPD) is a complex condition with significant impact on prognosis, especially in advanced stages where symptom burden becomes critical. Breathlessness affects patients’ quality of life, and despite various therapeutic strategies, the role of opioids in palliative care for COPD remains under investigation. The acceptance of a therapeutic trial of different types of opioids is increasing not only in end-of-life situations but also for stable COPD patients experiencing intolerable refractory breathlessness despite optimal conventional therapy. Recent clinical trials have raised questions about the overall clinical benefit of opioids in addressing breathlessness in COPD, prompting the need to clarify inconsistencies and identify specific subgroups that may benefit from opioid therapy. In the clinical setting, it is crucial to understand the attributes of patients who exhibit positive responses to opioids and what type of opioids could have a positive impact. This research paper aims to offer an update of the most recent evidence of opioid treatment in managing breathlessness among individuals with COPD with a head-to-head evaluation of the supporting and opposing proof in the medical literature.

show abstract

Effect of Opioid Abuse and Dependance on Outcomes of Patients Hospitalized With Copd: A 5-Year Analysis

Cited by 2 publications

References 0 publications

Burden of vaccine-preventable diseases among at-risk adult populations in the US

Burden of vaccine-preventable diseases among at-risk adult populations in the US

Opioids in Treatment of Refractory Dyspnea in Chronic Obstructive Pulmonary Disease: Yes, No or Maybe

Contact Info

Product

Resources

About